Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1-specific T cells in a pediatric donor and pediatric patient with relapsed leukemia

A case report and review of the literature

Shoji Saito, Ryu Yanagisawa, Kentaro Yoshikawa, Yumiko Higuchi, Terutsugu Koya, Kiyoshi Yoshizawa, Miyuki Tanaka, Kazuo Sakashita, Takashi Kobayashi, Takashi Kurata, Koichi Hirabayashi, Yozo Nakazawa, Masaaki Shiohara, Yoshikazu Yonemitsu, Masato Okamoto, Haruo Sugiyama, Kenichi Koike, Shigetaka Shimodaira

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

A 15-year-old girl with acute lymphoblastic leukemia received allogeneic dendritic cell vaccination, pulsed with Wilms tumor 1 (WT1) peptide, after her third hematopoietic stem cell transplantation (HSCT). The vaccines were generated from the third HSCT donor, who was her younger sister, age 12 years. The patient received 14 vaccines and had no graft-versus-host disease or systemic adverse effect, aside from grade 2 skin reaction at the injection site. WT1-specific immune responses were detected after vaccination by both WT1-tetramer analysis and enzyme-linked immunosorbent spot assay. This strategy may be safe, tolerable and even feasible for patients with a relapse after HSCT.

Original languageEnglish
Pages (from-to)330-335
Number of pages6
JournalCytotherapy
Volume17
Issue number3
DOIs
Publication statusPublished - Mar 1 2015

Fingerprint

Wilms Tumor
Hematopoietic Stem Cell Transplantation
Dendritic Cells
Leukemia
Vaccination
Tissue Donors
Pediatrics
T-Lymphocytes
Safety
Vaccines
Graft vs Host Disease
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Siblings
Enzyme-Linked Immunosorbent Assay
Recurrence
Skin
Peptides
Injections

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Genetics(clinical)
  • Cell Biology
  • Transplantation
  • Cancer Research

Cite this

Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1-specific T cells in a pediatric donor and pediatric patient with relapsed leukemia : A case report and review of the literature. / Saito, Shoji; Yanagisawa, Ryu; Yoshikawa, Kentaro; Higuchi, Yumiko; Koya, Terutsugu; Yoshizawa, Kiyoshi; Tanaka, Miyuki; Sakashita, Kazuo; Kobayashi, Takashi; Kurata, Takashi; Hirabayashi, Koichi; Nakazawa, Yozo; Shiohara, Masaaki; Yonemitsu, Yoshikazu; Okamoto, Masato; Sugiyama, Haruo; Koike, Kenichi; Shimodaira, Shigetaka.

In: Cytotherapy, Vol. 17, No. 3, 01.03.2015, p. 330-335.

Research output: Contribution to journalArticle

Saito, S, Yanagisawa, R, Yoshikawa, K, Higuchi, Y, Koya, T, Yoshizawa, K, Tanaka, M, Sakashita, K, Kobayashi, T, Kurata, T, Hirabayashi, K, Nakazawa, Y, Shiohara, M, Yonemitsu, Y, Okamoto, M, Sugiyama, H, Koike, K & Shimodaira, S 2015, 'Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1-specific T cells in a pediatric donor and pediatric patient with relapsed leukemia: A case report and review of the literature', Cytotherapy, vol. 17, no. 3, pp. 330-335. https://doi.org/10.1016/j.jcyt.2014.10.003
Saito, Shoji ; Yanagisawa, Ryu ; Yoshikawa, Kentaro ; Higuchi, Yumiko ; Koya, Terutsugu ; Yoshizawa, Kiyoshi ; Tanaka, Miyuki ; Sakashita, Kazuo ; Kobayashi, Takashi ; Kurata, Takashi ; Hirabayashi, Koichi ; Nakazawa, Yozo ; Shiohara, Masaaki ; Yonemitsu, Yoshikazu ; Okamoto, Masato ; Sugiyama, Haruo ; Koike, Kenichi ; Shimodaira, Shigetaka. / Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1-specific T cells in a pediatric donor and pediatric patient with relapsed leukemia : A case report and review of the literature. In: Cytotherapy. 2015 ; Vol. 17, No. 3. pp. 330-335.
@article{49150daf7ce049049fb5fe2e6b8fbb31,
title = "Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1-specific T cells in a pediatric donor and pediatric patient with relapsed leukemia: A case report and review of the literature",
abstract = "A 15-year-old girl with acute lymphoblastic leukemia received allogeneic dendritic cell vaccination, pulsed with Wilms tumor 1 (WT1) peptide, after her third hematopoietic stem cell transplantation (HSCT). The vaccines were generated from the third HSCT donor, who was her younger sister, age 12 years. The patient received 14 vaccines and had no graft-versus-host disease or systemic adverse effect, aside from grade 2 skin reaction at the injection site. WT1-specific immune responses were detected after vaccination by both WT1-tetramer analysis and enzyme-linked immunosorbent spot assay. This strategy may be safe, tolerable and even feasible for patients with a relapse after HSCT.",
author = "Shoji Saito and Ryu Yanagisawa and Kentaro Yoshikawa and Yumiko Higuchi and Terutsugu Koya and Kiyoshi Yoshizawa and Miyuki Tanaka and Kazuo Sakashita and Takashi Kobayashi and Takashi Kurata and Koichi Hirabayashi and Yozo Nakazawa and Masaaki Shiohara and Yoshikazu Yonemitsu and Masato Okamoto and Haruo Sugiyama and Kenichi Koike and Shigetaka Shimodaira",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.jcyt.2014.10.003",
language = "English",
volume = "17",
pages = "330--335",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1-specific T cells in a pediatric donor and pediatric patient with relapsed leukemia

T2 - A case report and review of the literature

AU - Saito, Shoji

AU - Yanagisawa, Ryu

AU - Yoshikawa, Kentaro

AU - Higuchi, Yumiko

AU - Koya, Terutsugu

AU - Yoshizawa, Kiyoshi

AU - Tanaka, Miyuki

AU - Sakashita, Kazuo

AU - Kobayashi, Takashi

AU - Kurata, Takashi

AU - Hirabayashi, Koichi

AU - Nakazawa, Yozo

AU - Shiohara, Masaaki

AU - Yonemitsu, Yoshikazu

AU - Okamoto, Masato

AU - Sugiyama, Haruo

AU - Koike, Kenichi

AU - Shimodaira, Shigetaka

PY - 2015/3/1

Y1 - 2015/3/1

N2 - A 15-year-old girl with acute lymphoblastic leukemia received allogeneic dendritic cell vaccination, pulsed with Wilms tumor 1 (WT1) peptide, after her third hematopoietic stem cell transplantation (HSCT). The vaccines were generated from the third HSCT donor, who was her younger sister, age 12 years. The patient received 14 vaccines and had no graft-versus-host disease or systemic adverse effect, aside from grade 2 skin reaction at the injection site. WT1-specific immune responses were detected after vaccination by both WT1-tetramer analysis and enzyme-linked immunosorbent spot assay. This strategy may be safe, tolerable and even feasible for patients with a relapse after HSCT.

AB - A 15-year-old girl with acute lymphoblastic leukemia received allogeneic dendritic cell vaccination, pulsed with Wilms tumor 1 (WT1) peptide, after her third hematopoietic stem cell transplantation (HSCT). The vaccines were generated from the third HSCT donor, who was her younger sister, age 12 years. The patient received 14 vaccines and had no graft-versus-host disease or systemic adverse effect, aside from grade 2 skin reaction at the injection site. WT1-specific immune responses were detected after vaccination by both WT1-tetramer analysis and enzyme-linked immunosorbent spot assay. This strategy may be safe, tolerable and even feasible for patients with a relapse after HSCT.

UR - http://www.scopus.com/inward/record.url?scp=84924958796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924958796&partnerID=8YFLogxK

U2 - 10.1016/j.jcyt.2014.10.003

DO - 10.1016/j.jcyt.2014.10.003

M3 - Article

VL - 17

SP - 330

EP - 335

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 3

ER -